Interfering with S100B-effector protein interactions for cancer therapy

Drug Discov Today. 2020 Sep;25(9):1754-1761. doi: 10.1016/j.drudis.2020.07.010. Epub 2020 Jul 15.

Abstract

S100 calcium-binding protein B (S100B) is overexpressed in various malignant tumors, where it regulates cancer cell proliferation and metabolism by physical interactions with other molecules. Interfering with S100B-effector protein interactions is a potential strategy to treat malignant tumors. Although some S100B inhibitors have been discovered by virtual screening (VS), most target the S100B-p53 interaction. Hence, there is scope for the discovery of other S100B-effector protein interaction modulators for malignant tumors. In this review, we provide an overview of S100B-effector protein interaction inhibitor discovery using VS and discuss promising S100B-effector protein interaction targets that permit in silico analysis for drug discovery.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Humans
  • Neoplasms / drug therapy*
  • Neoplasms / metabolism
  • S100 Calcium Binding Protein beta Subunit / antagonists & inhibitors*
  • S100 Calcium Binding Protein beta Subunit / metabolism

Substances

  • S100 Calcium Binding Protein beta Subunit